RAPPORT THERAPEUTICS INC.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Stock Performance Snapshot
Financial Health
RAPPORT THERAPEUTICS INC. shows strong financial health with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RAPP
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones
Clinical data and regulatory milestones tend to move valuation; track trial readouts and programme updates, though outcomes can be binary and uncertain.
Financing & Runway
Cash position and fundraising plans shape dilution risk and development pace; a need to raise capital can affect shareholders.
Partnership Potential
Collaborations with larger pharmaceutical companies can de‑risk programmes and provide funding, but partnerships are not guaranteed and take time to execute.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
